Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study.

Conclusions -Among a cohort of 99,744 older Medicare patients with gout, overall there was no difference in the risk of MI, stroke, new onset HF, coronary revascularization, or all-cause mortality between patients initiating febuxostat compared with allopurinol. However, there seemed to be a trend toward an increased, albeit not statistically significant, risk for all-cause mortality in patients who used febuxostat for over 3 years versus allopurinol for over 3 years. The risk of HF exacerbation was slightly lower in febuxostat initiators.
PMID: 29899013 [PubMed - as supplied by publisher]

Source: Circulation - June 13, 2018 Category: Cardiology Authors: Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC Tags: Circulation Source Type: research